Reduced atherosclerotic lesions in P2Y1/apolipoprotein E double-knockout mice -: The contribution of non-hematopoietic-derived P2Y1 receptors

被引:59
作者
Hechler, Beatrice
Freund, Monique
Ravanat, Catherine
Magnenat, Stephanie
Cazenave, Jean-Pierre
Gachet, Christian [1 ]
机构
[1] Etab Francais Sang Alsace, INSERM U 311, F-67065 Strasbourg, France
关键词
atherosclerosis; blood cells; immunohistochemistry; plaque; transplantation;
D O I
10.1161/CIRCULATIONAHA.108.788927
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-The P2Y(1) receptor plays a key role in arterial thrombosis and is widely expressed in many cell types involved in atherosclerosis. The aim of this study was to evaluate its potential involvement in the development of atherosclerotic lesions. Methods and Results-Apolipoprotein E-deficient (ApoE(-/-)) and P2Y(1)(-/-)/ApoE(-/-) mice were maintained on regular chow for 17 or 30 weeks before analysis of atherosclerotic lesions. At 17 weeks, lesions in the aortic sinus and entire aorta were smaller in P2Y(1)(-/-)/ApoE(-/-) compared with those in ApoE(-/-) animals. At 30 weeks, the aortic sinus lesions in P2Y(1)(-/-)/ApoE(-/-) mice were still diminished in size and displayed reduced inflammation, reflected by decreased macrophage infiltration and diminished VCAM-1 immunostaining, compared with those in ApoE(-/-) mice. They also had a lower smooth muscle cell content. Unexpectedly, bone marrow transplantation showed that the absence of the P2Y(1) receptor in blood cells only led to no significant modification of the lesion compared with control ApoE(-/-) reconstituted animals. Conversely, the absence of the P2Y(1) receptor except in blood cells resulted in a reduction in lesion size similar to that in control P2Y(1)(-/-)/ApoE(-/-) reconstituted mice, pointing to a role of non-hematopoietic-derived P2Y(1) receptors, most likely the endothelial or smooth muscle cell P2Y(1) receptors. In addition, although this was not statistically significant, plasma cholesterol levels were consistently decreased in P2Y(1)(-/-) animals, suggesting that a modification of lipid metabolism could be responsible for the observed phenotype. Conclusion-The P2Y(1) receptor contributes to atherosclerosis, primarily through its role in non-hematopoietic-derived cells.
引用
收藏
页码:754 / 763
页数:10
相关论文
共 44 条
[1]   International union of pharmacology LVIII: Update on the P2Y G protein-coupled nucleotide receptors: From molecular mechanisms and pathophysiology to therapy [J].
Abbracchio, Maria P. ;
Burnstock, Geoffrey ;
Boeynaems, Jean-Marie ;
Barnard, Eric A. ;
Boyer, Jose L. ;
Kennedy, Charles ;
Knight, Gillian E. ;
Fumagalli, Marta ;
Gachet, Christian ;
Jacobson, Kenneth A. ;
Weisman, Gary A. .
PHARMACOLOGICAL REVIEWS, 2006, 58 (03) :281-341
[2]   Purinergic signaling and vascular cell proliferation and death [J].
Burnstock, G .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (03) :364-373
[3]  
Cazenave Jean-Pierre, 2004, Methods Mol Biol, V272, P13
[4]   PLATELET-INDUCED VASCULAR SMOOTH-MUSCLE CELL-PROLIFERATION IS MODULATED BY THE GROWTH AMPLIFICATION FACTORS SEROTONIN AND ADENOSINE-DIPHOSPHATE [J].
CROWLEY, ST ;
DEMPSEY, EC ;
HORWITZ, KB ;
HORWITZ, LD .
CIRCULATION, 1994, 90 (04) :1908-1918
[5]  
DAWICKI DD, 1995, AM J PHYSIOL-LUNG C, V268, pL666, DOI 10.1152/ajplung.1995.268.4.L666
[6]   P2 receptors: new potential players in atherosclerosis [J].
Di Virgilio, F ;
Solini, A .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135 (04) :831-842
[7]   Nucleotide receptors: an emerging family of regulatory molecules in blood cells [J].
Di Virgilio, F ;
Chiozzi, P ;
Ferrari, D ;
Falzoni, S ;
Sanz, JM ;
Morelli, A ;
Torboli, M ;
Bolognesi, G ;
Baricordi, OR .
BLOOD, 2001, 97 (03) :587-600
[8]   Phenotype changes of the vascular smooth muscle cell regulate P2 receptor expression as measured by quantitative RT-PCR [J].
Erlinge, D ;
Hou, M ;
Webb, TE ;
Barnard, EA ;
Möller, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 248 (03) :864-870
[9]   Regulation of platelet functions by P2 receptors [J].
Gachet, C .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2006, 46 :277-300
[10]   The platelet P2 receptors as molecular targets for old and new antiplatelet drugs [J].
Gachet, C .
PHARMACOLOGY & THERAPEUTICS, 2005, 108 (02) :180-192